The primary marketing focus of JUQ-097 is the lead actress, whose star power drives the title's commercial performance.
| Item | Details | |------|----------| | | JUQ‑097 (also referenced in some filings as JQ‑097 ). | | Developer | Janssen Pharmaceuticals (J&J) – the “JUQ” prefix follows Janssen’s internal naming convention for early‑stage CNS‑focused small‑molecule programs. | | Chemical class | Highly selective, non‑peptidic antagonist of the nociceptin/orphanin‑FQ peptide (NOP) receptor (also known as OPRL1 ). | | Molecular weight | ≈ 420 Da (exact value pending final publication). | | Formulation | Oral tablets (10 mg, 30 mg, 60 mg) for Phase II/III trials; a soluble‑capsule version is in pre‑clinical toxicology. | | Target indication(s) | Alcohol Use Disorder (AUD) and Major Depressive Disorder (MDD) with comorbid alcohol misuse . Secondary exploratory programs include opioid‑induced hyperalgesia and post‑traumatic stress disorder (PTSD). | JUQ-097
Initial studies have revealed that JUQ-097 possesses a range of intriguing properties. For instance, it has been shown to exhibit high affinity for its target protein, with a dissociation constant (Kd) in the nanomolar range. This suggests that the compound is capable of binding to its target with exceptional specificity and potency. Furthermore, JUQ-097 has been found to exhibit good pharmacokinetic properties, including oral bioavailability and a favorable half-life. The primary marketing focus of JUQ-097 is the